thalidomide has been researched along with Vascular Diseases in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bathula, S | 1 |
| Sardana, K | 1 |
| Mathachan, SR | 1 |
| Khurana, A | 1 |
| Ahuja, A | 1 |
| Paliwal, P | 1 |
| Daher, IN | 1 |
| Yeh, ET | 1 |
| SCHULZ, KH | 1 |
| JAENNER, M | 1 |
| GILLIS, L | 1 |
| McCarty, MF | 1 |
| Sommer, C | 1 |
| Marziniak, M | 1 |
| Myers, RR | 1 |
1 review available for thalidomide and Vascular Diseases
| Article | Year |
|---|---|
Vascular complications of selected cancer therapies.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimet | 2008 |
6 other studies available for thalidomide and Vascular Diseases
| Article | Year |
|---|---|
A real-world study of low-dose thalidomide in severe erythema nodosum leprosum highlighting its mechanistic rationale in a resource-constrained target population.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Pannicu | 2023 |
Thalidomide and lenalidomide: overview of the French pharmacovigilance database.
Topics: Databases, Factual; France; Hematologic Diseases; Humans; Immunosuppressive Agents; Lenalidomide; Mu | 2012 |
[ALLERGIC VASCULITIS WITH THROMBOCYTOPENIA CAUSED BY THALIDOMIDE].
Topics: Arteritis; Drug Hypersensitivity; Exanthema; Leg; Phlebitis; Purpura; Purpura, Thrombocytopenic; Tha | 1963 |
AMPUTATIONS, INCLUDING CONGENITAL ABNORMALITIES.
Topics: Abnormalities, Drug-Induced; Amputation Stumps; Amputation, Surgical; Artificial Limbs; Child; Ectro | 1964 |
Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis.
Topics: Animals; Antineoplastic Agents; Callithrix; Fish Oils; Gene Expression; Humans; Hyperplasia; Inflamm | 1997 |
The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve.
Topics: Analysis of Variance; Animals; Chronic Disease; Constriction; Disease Models, Animal; Female; Hypera | 1998 |